{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:23:31Z","timestamp":1789514611990,"version":"build-2803163510"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Congenital aniridia is a rare and severe panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% of cases is caused by PAX6 haploinsufficiency. The phenotype includes ptosis, nystagmus, corneal limbal insufficiency, glaucoma, cataract, optic nerve, and foveal hypoplasia. Ataluren eye drops aim to restore ocular surface PAX6 haploinsufficiency in aniridia-related keratopathy (ARK). However, there are currently no available forms of the ophthalmic solution. The objective of this study was to assess the physicochemical and microbiological stability of ataluren 1% eye drop in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient. The visual aspect, ataluren quantification by a stability-indicating chromatographic method, and microbiological sterility were analyzed. The oily formulation in castor oil and DMSO (10%) better protects ataluren hydrolysis and oxidative degradation and permits its complete solubilization. Throughout the 60 days period, the oily solution in the LDPE bottle remained clear without any precipitation or color modification, and no drug loss and no microbial development were detected. The demonstrated physical and microbiological stability of ataluren 1% eye drop formulation at 22\u201325 \u00b0C might facilitate clinical research in aniridia.<\/jats:p>","DOI":"10.3390\/pharmaceutics13010007","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T20:39:29Z","timestamp":1608669569000},"page":"7","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia"],"prefix":"10.3390","volume":"13","author":[{"given":"Celia","family":"Djayet","sequence":"first","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-5482","authenticated-orcid":false,"given":"Dominique","family":"Bremond-Gignac","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service d\u2019ophtalmologie, CRMR OPHTARA, Universit\u00e9 de Paris, 75015 Paris, France"},{"name":"INSERM UMRS 1138, Team 17, Centre de Recherche des Cordeliers, Universit\u00e9 Sorbonne Paris Cit\u00e9, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Touchard","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-3695","authenticated-orcid":false,"given":"Philippe-Henri","family":"Secretan","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"},{"name":"Mat\u00e9riaux et Sant\u00e9, Universit\u00e9 Paris-Saclay, 92296 Chatenay-Malabry, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Vidal","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-8117","authenticated-orcid":false,"given":"Matthieu P.","family":"Robert","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service d\u2019ophtalmologie, CRMR OPHTARA, Universit\u00e9 de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Daruich","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service d\u2019ophtalmologie, CRMR OPHTARA, Universit\u00e9 de Paris, 75015 Paris, France"},{"name":"INSERM UMRS 1138, Team 17, Centre de Recherche des Cordeliers, Universit\u00e9 Sorbonne Paris Cit\u00e9, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-3574","authenticated-orcid":false,"given":"Salvatore","family":"Cisternino","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"},{"name":"INSERM UMRS 1144, Optimisation Th\u00e9rapeutique en Neuropsychopharmacologie, Facult\u00e9 de Pharmacie, Universit\u00e9 de Paris, 75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4443-8843","authenticated-orcid":false,"given":"Jo\u00ebl","family":"Schlatter","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, AP-HP, H\u00f4pital Universitaire Necker-Enfants Malades, Service de Pharmacie, Universit\u00e9 de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ejhg.2012.100","article-title":"Aniridia","volume":"20","author":"Hingorani","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_2","first-page":"422","article-title":"Three patients with hallucal polydactyly and WAGR syndrome, including discordant expression of Wilms tumor in MZ twins","volume":"134","author":"Copin","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ajhg.2016.03.004","article-title":"Recessive and Dominant De Novo ITPR1 Mutations Cause Gillespie Syndrome","volume":"98","author":"Gerber","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107815","DOI":"10.1016\/j.exer.2019.107815","article-title":"Aniridia and Axenfeld-Rieger Syndrome: Clinical presentations, molecular genetics and current\/emerging therapies","volume":"189","author":"Chrystal","year":"2019","journal-title":"Exp. Eye. Res."},{"key":"ref_5","first-page":"67","article-title":"Congenital aniridia in children","volume":"69","year":"2019","journal-title":"Rev. Prat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ICU.0000000000000405","article-title":"PAX6 aniridia syndrome: Clinics, genetics, and therapeutics","volume":"28","author":"Lim","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1167\/iovs.13-11780","article-title":"In vivo morphology of the limbal palisades of vogt correlates with progressive stem cell deficiency in aniridia-related keratopathy","volume":"54","author":"Lagali","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1002\/mgg3.1198","article-title":"Nonsense suppression induced readthrough of a novel PAX6 mutation in patient-derived cells of congenital aniridia","volume":"3","author":"Liu","year":"2020","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omtn.2017.05.002","article-title":"Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia","volume":"7","author":"Wang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI70462","article-title":"Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects","volume":"124","author":"Wang","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_11","unstructured":"PTC Therapeutics (2020, October 19). STAR: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia. ClinicalTrials.gov: NCT02647359, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02647359#contactlocation."},{"key":"ref_12","unstructured":"European Medicines Agency (2020, October 19). Translarna\u2122 (Ataluren) Summary of Product Characteristics (2019). Available online: www.ema.europa.eu\/en\/documents\/product-information\/translarna-epar-product-information_en.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev-med-120611-144851","article-title":"Ataluren as an agent for therapeutic nonsense suppression","volume":"64","author":"Peltz","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","unstructured":"Drug Bank Database (2020, December 04). Ataluren. Available online: https:\/\/go.drugbank.com\/drugs\/DB05016."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-009-9189-2","article-title":"Improving tenoxicam solubility and bioavailability by cosolvent system","volume":"10","author":"Yeh","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cpdd.645","article-title":"Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects","volume":"8","author":"Kong","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_18","unstructured":"European Medicines Agency (2020, October 20). ICH Topic Q1A(R2): Stability Testing of New Drug Substances and Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf."},{"key":"ref_19","unstructured":"EDQM (European Directorate for the Quality of Medicines & Healthcare) (2020). European Pharmacopoeia 10.5; 2020, 5.1.4 Sterility Assay 04\/2011:20601, EDQM Council of Europe."},{"key":"ref_20","unstructured":"Food Drug and Administration (2020, October 20). Guidance for Industry: Drug Stability Guidelines, Available online: https:\/\/www.fda.gov\/media\/69957\/download."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.vascn.2010.10.004","article-title":"Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants","volume":"63","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jphotochem.2016.09.009","article-title":"Visible light-mediated photodegradation of imidazoline drugs in the presence of Riboflavin: Possible undesired effects on imidazoline-based eye drops","volume":"332","author":"Challier","year":"2017","journal-title":"J. Photochem. Photobiol. A Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.proeng.2012.01.1313","article-title":"Comparison of photocatalytic reaction of commercial P25 and synthetic TiO2-AgCl nanoparticles","volume":"32","author":"Sangchay","year":"2012","journal-title":"Procedia Eng."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/exer.1999.0754","article-title":"Formation of hydroxyl radicals in the human lens is related to the severity of nuclear cataract","volume":"70","author":"Garner","year":"2000","journal-title":"Exp. Eye Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105102","DOI":"10.1016\/j.ejps.2019.105102","article-title":"Stability of frozen 1% voriconazole eye-drops in both glass and innovative containers","volume":"141","author":"Roche","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jfo.2011.04.013","article-title":"A relevant choice for corticoid eye drops: Solution or suspension?","volume":"34","author":"Nourry","year":"2011","journal-title":"J. Fr. Ophtalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0886-3350(98)80264-2","article-title":"Dose uniformity of ophthalmic suspensions","volume":"24","author":"Diestelhorst","year":"1998","journal-title":"J. Cataract. Refract. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-2008-1035294","article-title":"Dosage problems in suspension eyedrops","volume":"209","author":"Kwon","year":"1996","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_29","first-page":"S215","article-title":"Innovations in topical ocular corticosteroid therapy for the management of postoperative ocular inflammation and pain","volume":"25","author":"Salinger","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"ref_30","first-page":"129","article-title":"A Novel Transdermal ophthalmic preparation for blepharitis in a dilute povidone-iodine and dimethyl sulfoxide (DMSO) system: A case series","volume":"9","author":"Pelletier","year":"2018","journal-title":"EC Ophthalmol."},{"key":"ref_31","first-page":"61","article-title":"Dimethyl sulfoxide (DMSO): A review","volume":"76","author":"Brayton","year":"1986","journal-title":"Cornell. Vet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2478\/v10181-012-0104-5","article-title":"Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs","volume":"15","author":"Balicki","year":"2012","journal-title":"Pol. J. Vet. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1208\/ps040102","article-title":"Ocular tolerance of absorption enhances in ophthalmic preparations","volume":"4","author":"Furrer","year":"2002","journal-title":"AAPS Pharm. Sci."},{"key":"ref_34","first-page":"61","article-title":"Effects of dimethyl sulfoxide on ocular inflammation","volume":"9","author":"Hanna","year":"1977","journal-title":"Ann. Ophthalmol."},{"key":"ref_35","first-page":"74","article-title":"Dimethyl sulfoxide USP, Ph.Eur in approved pharmaceutical products and medical devices","volume":"32","author":"Mckim","year":"2008","journal-title":"Pharm. Technol."},{"key":"ref_36","first-page":"30","article-title":"Advances in the regulated pharmaceutical use of dimethyl sulfoxide USP, Ph. Eur","volume":"3","author":"Mckim","year":"2016","journal-title":"Pharmaceut. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: An overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"ref_38","first-page":"17","article-title":"Effects of dimethyl sulfoxide on a model of corneal alkali injury","volume":"22","author":"Skrypuch","year":"1987","journal-title":"Can. J. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archopht.1986.01050150128043","article-title":"Ocular toxicity of intravitreal vidarabine solubilized in dimethyl sulfoxide","volume":"104","author":"Yoshizumi","year":"1986","journal-title":"Arch. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00006982-198808030-00012","article-title":"Experimental intravitreal ketoconazole in DMSO","volume":"8","author":"Yoshizumi","year":"1988","journal-title":"Retina"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/10520295.2017.1371333","article-title":"Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn","volume":"92","author":"Altan","year":"2017","journal-title":"Biotech. Histochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.burns.2016.09.026","article-title":"Dimethyl sulfoxide but not indomethacin is efficient for healing in hydrofluoric acid eye burns","volume":"43","author":"Altan","year":"2017","journal-title":"Burns"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1208\/s12249-019-1555-0","article-title":"Brinzolamide dimethyl sulfoxide In Situ Gelling Ophthalmic Solution: Formulation Optimisation and In Vitro and In Vivo Evaluation","volume":"21","author":"Bhalerao","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"ref_44","unstructured":"(2020, December 08). OECD Guideline for Testing of Chemical, Acute Eye Irritation\/Corrosion 405: 2017. Available online: https:\/\/www.oecd.org\/env\/test-no-405-acuteeye-irritation-corrosion-9789264185333-en.htm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1167\/iovs.06-0771","article-title":"Cryopreservation and lentiviral-mediated genetic modification of human primary cultured corneal endothelial cells","volume":"48","author":"Suh","year":"2007","journal-title":"Investig. Ophtalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/ptr.2804","article-title":"Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis","volume":"23","author":"Medhi","year":"2009","journal-title":"Phyther. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3923\/rjmp.2012.511.520","article-title":"Antioxidant activities of methyl ricinoleate and ricinoleic acid dominated Ricinus communis seeds extract using lipid peroxidation and free radical scavenging methods","volume":"6","author":"Oloyede","year":"2012","journal-title":"Res. J. Med. Plants"},{"key":"ref_48","first-page":"25","article-title":"Ricinus communis linn: A phytopharmacological review","volume":"4","author":"Jena","year":"2012","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sandford, E.C., Muntz, A., and Craig, J.P. (2020). Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye. Clin. Exp. Optom.","DOI":"10.1111\/cxo.13148"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clae.2009.10.005","article-title":"Effect of castor oil emulsion eyedrops on tear film composition and stability","volume":"33","author":"Maissa","year":"2010","journal-title":"Contact Lens Anterior Eye"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Muntz, A., Sandford, E., Classen, M., Curd, L., Jackson, A.K., Watters, G., Wang, M.T.M., and Craig, J.P. (2020). Randomized trial of topical periocular castor oil treatment for blepharitis. Ocul. Surf., in press.","DOI":"10.1016\/j.jtos.2020.05.007"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/1\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:22Z","timestamp":1760179702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/1\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["pharmaceutics13010007"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13010007","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,22]]}}}